COMPANY UPDATES
06
Jun
2018
Novoheart Receives C$400,000 in Research Funding from the Innovation and Technology Commission of Hong Kong

Novoheart Limited, a wholly owned subsidiary of global stem cell biotechnology company, Novoheart Holdings Inc., has been awarded a non-dilutional government grant of C$400,000 from the Innovation and Technology Commission (ITC) of Hong Kong. The grant has been awarded to Novoheart to further enhance the drug screening capabilities of its proprietary human ventricular cardiac tissue strip, as part of its unique MyHeartTM Platform of bioengineered human heart tissues. Including this latest grant, Novoheart has received close to C$2.2 million R&D funding from the ITC.


For more detailed press release, please click here.